Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1-Deaza-Adenosine is a synthetic small molecule and an analog of adenosine in which the nitrogen at position 1 of the purine ring is replaced by a carbon. It acts as a potent inhibitor of adenosine deaminase (ADA), with a Ki value of approximately 0.66 μM[4][5][8]. By inhibiting ADA, it prevents the deamination and subsequent breakdown of adenosine and related nucleosides. This mechanism leads to increased levels of adenosine in cells and tissues. Preclinical studies have shown that 1-Deaza-Adenosine exhibits antitumor activity in vitro against various leukemia cell lines such as HeLa, KB, P388, and L1210[5][8]. It has been investigated primarily for its potential use as a chemotherapy agent for lymphoproliferative disorders but remains experimental with no approved clinical indications[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-deaza-adenosine.